[Clinical and experimental studies on effects of chronic hepatitis B treated with astragali composita].
Eighty-seven cases of chronic persistent hepatitis (CPH) and 29 cases of chronic active hepatitis (CAH) were treated with Astragali Composita (AC), the clinical markedly effective rates were 69.0% and 55.2%, the total effective rates were 90.8% and 89.7% respectively; the sero-negative conversion rates of HBeAg and HBV-DNA were 27.7% and 28.0% respectively, they were higher than that of control group (P < 0.05-0.01). Eight ducks infected hepatitis B virus were treated with AC, sero-negative conversion of DHBV-DNA was seen in 3 ducks, DHBV-DNA levels of duck sera were lower after treatment than that before treatment (P < 0.05); mild inflammatory changes in liver tissues were seen in 3 ducks, its pathologic changes were milder than that of control groups; DHBV-DNA in liver tissues of 2 ducks was negative in situhybridization. The results indicated that AC had obvious effects of protecting liver tissues and some effects of inhibiting sera HBV and HBV replication.
Liu
K Z
KZ
Institute of Infectious Diseases, Zhejiang Medical University, Hangzhou.
Xu
C H
CH
Zhang
M T
MT
D000293:Adolescent; D000328:Adult; D000818:Animals; D004279:DNA, Viral / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004372:Ducks; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D015611:Hepatitis B Virus, Duck / Q000235:genetics; D006513:Hepatitis B e Antigens / Q000378:metabolism; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged
D004279:DNA, Viral; D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens